Literature DB >> 10727601

Internal dosimetry for systemic radiation therapy.

D R Fisher1.   

Abstract

The key to effective use of the medical internal radiation dose (MIRD) schema in radioimmunotherapy (RIT) is to understand how it works and what the essential data input requirements are. The fundamental data are acquired from medical imaging. Image interpretation involves (1) collecting data to determine the source-organ activities, (2) plotting the source-organ time-activity curves, (3) integrating the time-activity curves for an estimate of the residence time, and (4) applying the residence time values (for each important source organ) within the MIRD schema to calculate the tissue absorbed dose to target organs and tumors of interest. This article reviews methods for calculating internal dose. It also describes methods for selecting sampling times, integrating the area under the data curves, and customizing a dose assessment for a patient who does not resemble the MIRD phantom. A sample dose assessment is given, together with common mistakes to avoid. Three approaches to red marrow dosimetry are described. With the increased use of RIT agents for cancer treatment, a solid understanding of internal dose methods is essential for treatment planning and follow-up evaluations.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10727601     DOI: 10.1016/s1053-4296(00)80049-1

Source DB:  PubMed          Journal:  Semin Radiat Oncol        ISSN: 1053-4296            Impact factor:   5.934


  4 in total

1.  Solid-tumor radionuclide therapy dosimetry: new paradigms in view of tumor microenvironment and angiogenesis.

Authors:  Xuping Zhu; Matthew R Palmer; G Mike Makrigiorgos; Amin I Kassis
Journal:  Med Phys       Date:  2010-06       Impact factor: 4.071

2.  Pretargeting CD45 enhances the selective delivery of radiation to hematolymphoid tissues in nonhuman primates.

Authors:  Damian J Green; John M Pagel; Eneida R Nemecek; Yukang Lin; Aimee Kenoyer; Anastasia Pantelias; Donald K Hamlin; D Scott Wilbur; Darrell R Fisher; Joseph G Rajendran; Ajay K Gopal; Steven I Park; Oliver W Press
Journal:  Blood       Date:  2009-06-10       Impact factor: 22.113

3.  90Y-labeled anti-CD45 antibody allogeneic hematopoietic cell transplantation for high-risk multiple myeloma.

Authors:  William I Bensinger; Damian J Green; Sherilyn A Tuazon; Brenda M Sandmaier; Theodore A Gooley; Darrell R Fisher; Leona A Holmberg; Pamela S Becker; Sally J Lundberg; Johnnie J Orozco; Ajay K Gopal; Brian G Till; David G Coffey; Margaret E Nartea; Manuela C Matesan; John M Pagel; Joseph G Rajendran; Oliver W Press
Journal:  Bone Marrow Transplant       Date:  2020-07-24       Impact factor: 5.483

4.  Evaluation of effective dose for a patient under Ga-67 nuclear examination using TLD, water phantom and a simplified model.

Authors:  Kuang Hua Chu; Yu Ting Lin; Chia Chun Hsu; Chien Yi Chen; Lung Kwang Pan
Journal:  J Radiat Res       Date:  2012-08-21       Impact factor: 2.724

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.